Refractory hepatic hydrothorax: successful treatment with octreotide

Barreales, M.; Sáenz-López, S.; Igarzabal, A.; Muņoz‐Yagüe, Teresa; Casís, Begoña; Alonso-Navas, F.; Herruzo, J. A. Solís

doi:10.4321/s1130-01082005001100007

Cited by 12 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are currently no large studies or randomized trials that have examined these medications in HH, and evidence is largely limited to case reports or case series. (37)(38)(39)(40) Splanchnic and peripheral vasoconstrictors including octreotide, midodrine, and terlipressin increase effective arterial volume and decrease activation of the renin-angiotensin-aldosterone (RAA) system, increasing renal sodium excretion.…”

Section: Other Medical Therapy: Splanchnic and Peripheral Vasoconstrictorsmentioning

confidence: 99%

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

et al. 2020

View full text Add to dashboard Cite

Section: Other Medical Therapy: Splanchnic and Peripheral Vasoconstrictorsmentioning

confidence: 99%

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

et al. 2020

View full text Add to dashboard Cite

“…The amount of fluid in the pleural cavity decreased after the fifth day. During a six-month period of observation, there was no relapse of HH[ 24 ]. The positive effect of octreotide can be explained by its ability to suppress the activation of the renin-angiotensin-aldosterone system induced by diuretics, as well as to increase the excretion of Na + and water[ 25 ].…”

Section: Treatment Of Hhmentioning

confidence: 99%

Hepatic hydrothorax: An update and review of the literature

Garbuzenko

Arefyev

2017

WJH

View full text Add to dashboard Cite

This review considers the modern concepts of pathogenesis, diagnostic methods, and treatment principles of hepatic hydrothorax (HH). HH is the excessive (> 500 mL) accumulation of transudate in the pleural cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural diseases. It causes respiratory failure which aggravates the clinical course of liver cirrhosis, and the emergence of spontaneous bacterial pleural empyema may be the cause of death. The information was collected from the PubMed database, the Google Scholar retrieval system, the Cochrane reviews, and the reference lists from relevant publications for 1994-2016 using the keywords: “liver cirrhosis”, “portal hypertension”, “hepatic hydrothorax”, “pathogenesis”, “diagnostics”, and “treatment”. To limit the scope of this review, only articles dealing with uncomplicated hydrothorax in patients with liver cirrhosis were included. The analysis of the data showed that despite the progress of modern hepatology, the presence of HH is associated with poor prognosis and high mortality. Most patients suffering from it are candidates for orthotopic liver transplantation. In routine clinical practice, stratification of the risk for an adverse outcome and the subsequent determination of individual therapeutic strategies may be the keys to the successful management of the patient’s condition. The development of pathogenetic pharmacotherapy and optimization of minimally invasive treatment will improve the quality of life and increase the survival rate among patients with HH.

show abstract

“…A recent report of a case showed that terlipressin, a drug known to be beneficial in hepatorenal syndrome, might also be effective in the treatment of hepatic hydrothorax 49 . The successful use of octreotides 50,51 and nasal continuous positive airway pressure 52 have also been reported. However, studies in series of patients are needed to confirm these findings.…”

Section: Managementmentioning

confidence: 99%

Hepatic hydrothorax: Pathophysiology diagnosis and management

Roussos

Philippou

Mantzaris

et al. 2007

J of Gastro and Hepatol

View full text Add to dashboard Cite

Hepatic hydrothorax is defined as a significant pleural effusion (usually greater than 500 ml) in a cirrhotic patient, without an underlying pulmonary or cardiac disease. The diagnosis of hepatic hydrothorax should be suspected in a patient with established cirrhosis and portal hypertension, presenting with a unilateral pleural effusion, most commonly right-sided. In the vast majority of cases, patients with hepatic hydrothorax have end-stage liver disease. Therefore, they should be considered potential candidates for orthotopic liver transplantation. Until the performance of transplantation, other therapeutic modalities should be applied in order to relieve symptoms and prevent pulmonary complications.

show abstract

Refractory hepatic hydrothorax: successful treatment with octreotide

Cited by 12 publications

References 18 publications

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

Hepatic hydrothorax: An update and review of the literature

Hepatic hydrothorax: Pathophysiology diagnosis and management

Contact Info

Product

Resources

About